Paradoxical motor syndrome following a switch from atypical neuroleptics to aripiprazole.

Authors:
Beryl Koener
Beryl Koener
Institute of Neuroscience (Ions)
Eugene | United States
Emmanuel Hermans
Emmanuel Hermans
Université catholique de Louvain
Belgium

Am J Psychiatry 2007 Sep;164(9):1437-8

PDF Download - Full Text Link
( Please be advised that this article is hosted on an external website not affiliated with PubFacts.com)
Source Status
http://dx.doi.org/10.1176/appi.ajp.2007.07020363DOI ListingPossible
September 2007
3 Reads

Similar Publications

Acute dystonia associated with aripiprazole in a child.

J Am Acad Child Adolesc Psychiatry 2007 Mar;46(3):306-7

View Article
March 2007

Aripiprazole: pharmacology, efficacy, safety and tolerability.

Expert Rev Neurother 2005 May;5(3):297-307

Duke University Medical Center, Department of Psychiatry and Behavioral Sciences, Durham, NC 27710, USA.

Aripiprazole is a recently released antipsychotic medication which differs from other atypical antipsychotic agents by its partial agonist activity at postsynaptic D2 receptors. It is administered orally and is distinguished by a long elimination phase half-life relative to other antipsychotic medications. Randomized studies have demonstrated the efficacy of aripiprazole relative to placebo in the treatment of acute relapse of schizophrenia and schizoaffective disorder, maintenance treatment of schizophrenia, and treatment of acute bipolar mania. Read More

View Article
May 2005